» Articles » PMID: 32586737

Lumacaftor/ivacaftor Improves Liver Cholesterol Metabolism but Does Not Influence Hypocholesterolemia in Patients with Cystic Fibrosis

Overview
Journal J Cyst Fibros
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2020 Jun 27
PMID 32586737
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cystic fibrosis (CF) patients have reduced intestinal absorption of sterols and, despite enhanced endogenous synthesis, low plasma cholesterol. Lumacaftor/ivacaftor CFTR protein modulator therapy is used to improve the clinical outcome of CF patients homozygous for F508del mutation (homo-deltaF508). Aim of the study is to evaluate the cholesterol metabolism and hepatobiliary injury/function in adult homo-deltaF508 patients, before and after lumacaftor/ivacaftor treatment. Baseline parameters in homo-deltaF508 patients were compared to those in CF patients compound heterozygous for F508del mutation and another severe mutation (hetero-deltaF508).

Methods: Cholesterol metabolism was evaluated measuring plasma phytosterols and cholestanol, as intestinal absorption markers, and lathosterol, as liver biosynthesis marker. We quantified serum vitamin E, as nutritional marker. We evaluated liver injury by aspartate aminotransferase (AST) and alanine transaminase (ALT), biliary injury by γ-glutamyltransferase (γGT) and AP, and the liver function by bilirubin and albumin.

Results: Before the treatment, homo-deltaF508 patients (n = 20) had significantly lower cholesterol and vitamin E compared to hetero-deltaF508 (n = 20). Lumacaftor/ivacaftor treatment caused: 1) further reduction of cholesterol; 2) lathosterol reduction, suggesting a normalization of endogenous synthesis; 3) cholestanol and vitamin E increment, indicating an improvement of lipid digestion/absorption. Vitamin E difference (after-before treatment) was positively associated to treatment months. Alkaline phosphatase was also reduced.

Conclusions: These data suggest an effect of lumacaftor/ivacaftor on cholesterol metabolism and enterohepatic flux in CF patients. However, lumacaftor/ivacaftor does not promote the increase of cholesterol serum concentration that on the contrary declines. Further studies are needed to research the real mechanism causing this reduction.

Citing Articles

Impaired intestinal free fatty acid transport followed by chylomicron malformation, not pancreatic insufficiency, cause metabolic defects in cystic fibrosis.

Teng L, Dedousis N, Adeshirlarijaney A, Kanshana J, Liu M, Hodges C J Lipid Res. 2024; 65(7):100551.

PMID: 39002195 PMC: 11301217. DOI: 10.1016/j.jlr.2024.100551.


Changes in vitamins and trace elements after initiation of highly effective CFTR modulator therapy in children and adults with cystic fibrosis - a real-life insight.

Fabricius D, Knieling T, Zurmuehl N, Makedon L, Freihorst J, Schmidt H Mol Cell Pediatr. 2024; 11(1):4.

PMID: 38717689 PMC: 11078909. DOI: 10.1186/s40348-024-00178-6.


One year of treatment with elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes.

Castaldo A, Gelzo M, Iacotucci P, Longobardi A, Taccetti G, Terlizzi V Front Mol Biosci. 2024; 10:1327958.

PMID: 38259684 PMC: 10800484. DOI: 10.3389/fmolb.2023.1327958.


Raman Spectroscopy and Cystic Fibrosis Disease: An Alternative Potential Tool for Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Response Differentiation-A Pilot Study Based on Serum Samples.

Acri G, Testagrossa B, Lucanto M, Cristadoro S, Pellegrino S, Ruello E Molecules. 2024; 29(2).

PMID: 38257346 PMC: 10818724. DOI: 10.3390/molecules29020433.


Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations.

Sellers Z, Assis D, Paranjape S, Sathe M, Bodewes F, Bowen M Hepatology. 2023; 79(5):1220-1238.

PMID: 37934656 PMC: 11020118. DOI: 10.1097/HEP.0000000000000646.